The gene Rv1885c from the genome of Mycobacterium tuberculosis H 37 R v encodes a monofunctional and secreted chorismate mutase (*MtCM) with a 33-amino-acid cleavable signal sequence; hence, it belongs to the *AroQ class of chorismate mutases. Consistent with the heterologously expressed *MtCM having periplasmic destination in Escherichia coli and the absence of a discrete periplasmic compartment in M. tuberculosis, we show here that *MtCM secretes into the culture filtrate of M. tuberculosis. *MtCM functions as a homodimer and exhibits a dimeric state of the protein at a concentration as low as 5 nM. *MtCM exhibits simple Michaelis-Menten kinetics with a K m of 0.5 ؎ 0.05 mM and a k cat of 60 s ؊1 per active site (at 37°C and pH 7.5). The crystal structure of *MtCM has been determined at 1.7 Å resolution (Protein Data Bank identifier 2F6L).
Chorismate occupies a central place in the shikimate pathway for the biosynthesis of the aromatic amino acids: phenylalanine, tyrosine, and tryptophan (16) . Chorismate mutase (CM) (EC 5.4.99.5) catalyzes the conversion of chorismate to prephenate by Claisen rearrangement. CM accelerates the rearrangement by a factor of 10 6 compared to the uncatalyzed rearrangement at 25°C (1) . Several biochemical and structural studies on CM have been performed due to the diverse nature of CMs (6, 24, 26, 29, 51, 58) . Besides CM, the other enzymes that utilize chorismate are chorismate lyase, isochorismate synthase, anthranilate synthase, and p-aminobenzoate synthase (16) . Subsequent to the conversion of chorismate to prephenate by CM, prephenate dehydratase and prephenate dehydrogenase catalyze the biosynthesis of phenylalanine and tyrosine, respectively. Anthranilate synthase and a battery of other enzymes catalyze the biosynthesis of tryptophan from chorismate. CMs exist in multiple forms both functionally and structurally. Some examples of the monofunctional CMs from Bacillus subtilis (13) and Serratia rubidaea (55) lack allosteric control and exhibit simple Michaelis-Menten kinetics. Other examples of the monofunctional CMs from Saccharomyces cerevisiae (49) and Aspergillus nidulans (25) exhibit complex multi-end product effector control. Tryptophan is a potent allosteric activator, and phenylalanine and tyrosine are inhibitors of this class of CMs. On three occasions, CMs have evolved to become one catalytic component of a bifunctional protein: CM-prephenate dehydratase (8, 10) , CM-prephenate dehydrogenase (8, 21) , and CM-3-deoxy-D-arabino-heptulosonate 7-phosphate synthase (20) . The CMs from Escherichia coli (29) and S. cerevisiae (58) are all ␣-helical structures whereas the CMs from B. subtilis (6, 26) and Thermus thermophilus (17) have ␣/␤ barrel structures.
The shikimate pathway enzymes are essential for the biosynthesis of phenylalanine, tyrosine, tryptophan, and a number of other aromatic compounds in bacteria, fungi, algae, and plants, but this pathway is absent in mammals. One can take advantage of the nonoccurrence of CMs in humans and try to develop antimicrobial drugs to combat dreaded human pathogens such as Mycobacterium tuberculosis. With this intention, we gathered from the annotation of M. tuberculosis genome two putative genes for CM: Rv1885c and Rv0948c (5, 7) . The Rv1885c gene product has about 25% identity with the monofunctional CM of Erwinia herbicola (56) . The Rv0948c gene product has similarity to the amino terminus of some CMprephenate dehydratases. We reported earlier that Rv1885cCM has neither prephenate dehydratase nor prephenate dehydrogenase activities (S. Patterson, S.-K. Kim, G. Vasquez, S. K. Reddy, and P. T. Reddy, Am. Soc. Microbiol. Biodefense Res. Meet., abstr. 173, 2004) . The Rv1885c CM is synthesized with an amino terminal signal sequence which is cleaved off upon expression in E. coli with the mature protein beginning with Asp 34 . Two reports on the same theme of Rv1885c CM have appeared recently (42, 48) . According to a terminology coined earlier for the secreted CMs of AroQ class (4) and Rv1885c CM (48) , we will refer to this M. tuberculosis CM as *MtCM to infer its secretory property. In our study we have furthered the knowledge on the catalytic mechanism by crystal structure analysis and site-directed mutagenesis of the catalytic site residues. We have identified Arg 49 , Lys 60 , Arg 72 , Thr 105 , Glu 109 , and Arg 134 in the mature protein (numbering of amino acids includes the signal sequence) as the critical residues for catalysis. The crystal structure analysis of *MtCM shows that the protein folds into an all ␣-helical bundle similar to the structures of E. coli CM (EcCM) (29) and S. cerevisiae CM (ScCM) (58) . The catalytic site of *MtCM is formed within a single chain of the dimer with no contribution from the second chain, similar to the catalytic site of ScCM but different from the catalytic site of EcCM, which includes residues from both the chains. The coordinates for the structure of *MtCM were released first from our laboratory with the Protein Data Bank (PDB) identifier 2F6L. While this article was in preparation, we noticed a similar structural analysis of *MtCM by Ö kvist et al. (40) (PDB 2FP1/2FP2) and later by Qamra et al. (43) (PDB 2AO2). We report here that the *MtCM is secreted from M. tuberculosis into the culture medium. Our search for *MtCM homologues in other mycobacterial species revealed its existence in pathogenic species such as Mycobacterium bovis and Mycobacterium avium. Perhaps, *MtCM may have some implications in virulence of the human pathogen M. tuberculosis. Sasso et al. (48) discussed the available evidence for the idea that *MtCM may be involved in pathogenesis.
MATERIALS AND METHODS

Materials.
Restriction endonucleases, a Quick ligase kit, T4 polynucleotide kinase, and calf intestinal alkaline phosphatase were purchased from New England Biolabs, Beverly, MA. SeaKem GTG Agarose and NuSieve GTG Agarose were purchased from FMC BioProducts, Rockland, ME. The PCR product purification kit, gel extraction kit, and plasmid purification kit were from QIAGEN, Valencia, CA. DEAE cellulose (DE52) was from Whatman laboratories. A Big Dye dideoxy terminator cycle sequencing kit was purchased from Applied Biosystems, Inc. (Perkin Elmer Cetus, Foster City, CA). A QuikChange II XL site-directed mutagenesis kit was purchased from Stratagene, La Jolla, CA. L-Malic acid and NAD were obtained from Sigma Biochemicals, St. Louis, MO. Middlebrook 7H9 broth base was obtained from Difco laboratories, Detroit, MI. Oligonucleotides were obtained from Operon, QIAGEN, Valencia, CA. Crystal Screen Kit I was purchased from Hampton Research, Laguna Niguel, CA. E. coli strains and plasmids. The expression vector pRE1 for native protein production based on the P L promoter was described previously (45) . The E. coli strains for P L -based expression are C600 lysogen (r Ϫ m ϩ cI ϩ ) and MZ1 ( cI857ts [59] Ϫ m B Ϫ )gal dcm (DE3)] was used for expression of the cloned gene. The DE3 designation indicates that the host is a lysogen of DE3 that carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter.
DNA procedures. Ten milliliters of Luria-Bertani (LB) medium, supplemented with 100 g of ampicillin/ml, was inoculated with a colony of C600 ( cI ϩ ) or NovaBlue harboring a plasmid. Cells were grown overnight at 37°C. Plasmids were isolated by using a QIAGEN mini plasmid purification kit. Digestion of DNA with restriction enzymes was performed according to the manufacturer's recommendation. DNA fragments were separated by electrophoresis on SeaKem GTG agarose or NuSieve GTG agarose and used for ligation. Ligation of DNA fragments was performed using a Quick ligase kit. Competent cells of the E. coli strains used here were prepared by the Hanahan method (15) .
Cloning of Rv1885c and production of *MtCM in E. coli. The full-length Rv1885c gene coding sequence was amplified by PCR using the forward primer 5Ј-GGAATTCCATATGCTTACCCGTCCACGTGAG (with NdeI restriction recognition sequence in bold letters) and the reverse primer 5Ј-CGCGGATCC TCAGGCCGGCGGTAGGGC (with BamHI restriction recognition sequence in bold letters). Amplification conditions were as follows: 96°C for 60 s for initial melting of DNA, followed by 25 cycles of amplification, with each cycle consisting of melting at 96°C for 45 s, annealing at 50°C for 45 s, and polymerization at 72°C for 60 s. Polymerization was continued at the end for 10 min at 72°C. A total of 200 ng of M. tuberculosis H 37 R v chromosomal DNA (kindly provided by John Belisle and Patrick Brennan, Colorado State University) and 100 ng of primers were used in the amplification. The Rv1885c gene beginning at codon 34 was similarly amplified using the forward primer 5Ј-GGAATTCCATATGGACGGC ACCAGCCAGTTAGCC and the same reverse primer (restriction recognition sequence in bold letters). The amplified DNA was digested with NdeI and BamHI and cloned into the respective sites of the plasmid pRE1 (45) . A recombinant was isolated from C600 lysogen and introduced into the strain MZ1 for native protein production (45) . Similarly, the NdeI and BamHI fragments were also cloned into the respective sites of the expression vector pET15b, and a recombinant was isolated from E. coli NovaBlue. The pET15b recombinant was introduced into E. coli BL21(DE3) for *MtCM production based on the IPTG induction (52) .
For protein production trials using the pRE1 recombinant (45) , E. coli MZ1 harboring the recombinant plasmid pRE1 was grown in 50 ml of LB medium, supplemented with ampicillin (50 g/ml), at 32°C in a water bath shaker to an A 600 of Ϸ0.4. To induce *MtCM synthesis, 50 ml of LB medium kept at 65°C was added to the culture and immediately shifted to a 42°C shaking water bath. The culture was further supplemented with ampicillin. A time course of induction was carried out by harvesting 25 ml of induced cells at hourly intervals for up to 4 h. We observed that 2 h of induction gave optimal production of the mature protein from the full-length clone. The protein was produced to Ϸ5% of the total cellular protein and was completely soluble. We would like to point out that growth of the cells after induction was hampered by the production of the Rv1885c gene product, suggesting the toxic nature of the gene product. For protein production using the pET15b recombinant, E. coli BL21(DE3) harboring the recombinant plasmid was grown in LB medium at 37°C to an A 600 of Ϸ0.6. *MtCM synthesis was induced with 30 M IPTG at 25°C overnight.
Purification of *MtCM from cellular extract for crystallization. For purification of the protein produced from the full-length clone, the MZ1/pRE1 recombinant culture was scaled up to 4 liters of induced cells. Cells were harvested by centrifugation and washed with 25 mM Tris-HCl buffer, pH 7.5. Cells (5 g of wet weight) were suspended in 50 ml of 50 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol [DTT], 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride (lysis buffer). Cell extract was prepared by passing the cell suspension through a French press twice and by centrifugation at 100,000 ϫ g for 1 h. The supernatant was loaded onto a 40-ml DE52 column and eluted with a linear NaCl gradient generated from 200 ml of the lysis buffer and 200 ml of the lysis buffer containing 0.5 M NaCl. Fractions corresponding to the overproduced protein, as judged by the Coomassie stain on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, were concentrated and further purified on a 480-ml Sephadex-G75 superfine column (2.6 by 100 cm) equilibrated with the lysis buffer supplemented with 100 mM NaCl. Again, the purest protein fractions corresponding to the overproduced protein were pooled and concentrated. The final yield of the protein originating from the full-length clone was 10 mg, i.e., 2.5 mg/liter culture with a purity of Ϸ95%. For the purpose of crystallization, the protein was further purified on a 5-ml hydroxylapatite column. The protein was dialyzed against 20 mM potassium phosphate buffer, pH 7.4, containing 1 mM DTT. The protein was loaded and eluted with a phosphate buffer gradient generated from 50 ml each of 20 mM and 300 mM phosphate buffer, pH 7.4. Pure protein was dialyzed against 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, and 100 mM sodium chloride and concentrated to Ϸ10 mg/ml.
Isolation of the periplasmic proteins. Periplasmic proteins were isolated by the method of Neu and Heppel (38) with the slight modification described in the QIAGEN handbook. Induced cells from a 100-ml culture of BL21(DE3)/pET15b recombinant (300 mg of cells) were suspended in 30 ml of 20% sucrose-30 mM Tris-HCl, pH 8.0, at 24°C, and EDTA was added to a final concentration of 1 mM. The suspension was mixed in a rotary shaker at 150 rpm for 10 min at 24°C and centrifuged at 10,000 ϫ g for 15 min at 4°C. The cell pellet was suspended in 30 ml of ice-cold 5 mM MgSO 4 and kept on a rotary shaker at 150 rpm for 10 VOL. 188, 2006 CHORISMATE MUTASE OF M. TUBERCULOSIS 8639 min at 4°C. The osmotic-shocked cell suspension was centrifuged at 10,000 ϫ g for 20 min at 4°C, and the supernatant containing the periplasmic proteins was removed and buffered with 1 M Tris-HCl, pH 8.0, to a 30 mM final concentration. The osmotic-shocked cell pellet was suspended in 30 ml of 30 mM Tris-HCl, pH 8.0 and passaged through a French press. This represents cytoplasmic proteins. Total cellular extract and the cytoplasmic membranes were prepared from unshocked cells. Small-scale purification of *MtCM from the periplasmic proteins. Periplasmic proteins were isolated as described above from a 100-ml culture of E. coli BL21(DE3) harboring the pET15b recombinant. The periplasmic fluid was concentrated to Ϸ200 l in a Millipore centrifugal tube with a 5,000-molecular-weight cutoff and chromatographed on a 210-ml Biosep SEC-3000 highpressure liquid chromatography (HPLC) column (Phenomenex, Torrance, CA). The column was equilibrated and eluted with 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM DTT, and 100 mM NaCl. The purity of *MtCM isolated from the periplasm by a single chromatography step equaled that observed for the protein purified from the cellular extract as described above by a three-step procedure. Therefore, we purified all the mutant variants of *MtCM from the periplasm.
Growth of M. tuberculosis, isolation of culture filtrate, and preparation of cell extract. A clinical isolate of M. tuberculosis H 37 R v and a laboratory strain of M. tuberculosis H 37 R v were grown in Middlebrook 7H9 medium supplemented with glycerol, albumin-dextrose complex, and Tween 80 (23) in a roller bottle in a biosafety level 3 facility. After 1 week (early in the exponential phase of growth) and 3 weeks (late in the exponential phase of growth) at 37°C, cell cultures were centrifuged at 5,000 ϫ g. The culture supernatant (filtrate) was filtered through a Millipore membrane filter with 0.2-m-pore-size cutoff. The filter has low affinity for proteins. The culture filtrate was dialyzed overnight against 50 mM Tris-HCl, pH 7.5, to remove the medium constituents except albumin although we found that the growth medium has no effect on CM activity of the purified protein.
Cell extract of the laboratory strain of M. tuberculosis H 37 R v was prepared from a 100-ml culture in the late exponential phase of growth. Cells were collected by centrifugation and washed twice with lysis buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 100 mM NaCl). The cell pellet was suspended in 0.5 ml of lysis buffer in a microcentrifuge tube, and glass beads (100 m size) equivalent to a 0.5-ml volume were added. Cell extract was prepared in a bead beater by subjecting the cell-bead suspension to four 45-s pulses by intermittent cooling. Unbroken cells were centrifuged off at 14,000 rpm for 5 min in a microcentrifuge. The cell extract was filtered through a membrane filter (0.2-m-pore-size cutoff) for safe handling. One hundred microliters of the cell extract was diluted 80-fold (cell disruption under these conditions is Ͼ80%) with the lysis buffer in order to normalize the activity per unit volume of culture filtrate/cell extract. Separately, another 100 l of the cell extract was diluted with the growth medium to test the effect of growth medium on CM and malate dehydrogenase (MDH) activities. MDH, a citric acid cycle cytoplasmic enzyme (44) , was assayed as a control for cell lysis. Various volumes of the dialyzed culture filtrate and the diluted cell extract were assayed for CM and MDH.
MDH assay. The enzyme was assayed in a 1-ml volume containing 60 mM glycine buffer, pH 9.0, 1 mM NAD ϩ , and various volumes of the dialyzed culture supernatant. The reaction was started with 20 mM L-malate (sodium salt), and the reduction of NAD ϩ was followed at 340 nm (12) . The reaction was carried out at 24°C.
Site-directed mutagenesis. Mutagenesis of Arg 49 Ala, Lys 60 Ala, Asp 69 Ala, Arg 72 Ala, Thr 105 Ala, Glu 109 Ala, Glu 109 Gln, and Arg 134 Ala was accomplished using a QuikChange II XL Site-Directed Mutagenesis Kit. The numbering of the amino acid residues includes the amino terminal signal sequence. The sequence of the oligonucleotide pairs for each mutagenesis reaction is as follows: for Arg 49 Ala, 5Ј-GCCGCCGCTGAGGCGTTGGAGGTCGCC and 5Ј-GGCGACC TCCAACGCCTCAGCGGCGGC; for Lys 60 Ala, 5Ј-GGTGGCAGCCTTCGCG TGGCGTGCTCAGC and 5Ј-GCTGAGCACGCCACGCGAAGGCTGCCACC; for Asp 69 Ala, 5Ј-CTGCCCATTGAGGCTTCCGGCCGAGTC and 5Ј-GACTC GGCCGGAAGCCTCAATGGGCAG; for Arg 72 Ala, 5Ј-CATTGAGGATTCC GGCGCAGTCGAACAGCAACTCG and 5Ј-CGAGTTGCTGTTCGACTGCG CCGGAATCCTCAATG; for Thr 105 Ala, 5Ј-CAGATTCGCGCCGCCGAGGCA ATCGAG and 5Ј-CTCGATTGCCTCGGCGGCGCGAATCTG; for Glu 109 Ala, 5Ј-CACCGAGGCAATCGCGTACAGCCGGTTC and 5Ј-GAACCGGCTGTAC GCGATTGCCTCGGTG; for Glu 109 Gln, 5Ј-CACCGAGGCAATCCAGTACAGC CGGTTC and 5Ј-GAACCGGCTGTACTGGATTGCCTCGGTG; for Arg 134 Ala, 5Ј-CTATCGGCATCGGCATCGGCGATCGAA and 5Ј-GTCGATCGCCGATGC CGATGCCGATAG. Nucleotide bases in bold represent the mutation. Oligonucleotides were purified by HPLC and phosphorylated with polynucleotide kinase (46) . The mutagenesis efficiency was Ϸ90%. The template plasmid DNA for mutagenesis was the pET15b/Rv1885c recombinant. For each variant, the Rv1885c coding region was verified by DNA sequencing using primers T7P (5Ј-TAATACGACTCACTAT AGGG) and T7T (5Ј-GCTAGTTATTGCTCAGCGG).
CM assays and kinetic studies. CM was assayed as previously described (9) . Since the commercial preparation of chorismate is rather impure (Ϸ70%), we used pure chorismate (Ͼ99% pure; generous gift from Marcia Holden, Biochemical Science Division, National Institute of Standards and Technology) isolated from a CM auxotroph of E. coli which overproduces chorismate and exports it into the culture medium (14) . Reaction volumes of 0.4 ml of chorismate (typically, 1 mM) in 50 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 0.1 mg/ml bovine serum albumin, and 10 mM ␤-mercaptoethanol were incubated at 37°C for 5 min. The reaction was started with 5 pmol of *MtCM in a 10-l volume (i.e., 185 ng of *MtCM equivalent to a 12.5 nM final concentration of the dimer based on the molecular mass of 36,948 Da). Any variation in the amount of *MtCM used in the assay is specified in the figure legends. The reaction was allowed to proceed at 37°C and was terminated after 1 min to 5 min (depending on the mutation in the protein used in the assay) with 0.4 ml of 1 N HCl. After a further incubation at 37°C for 10 min to convert prephenate, which is formed in the enzymatic reaction, to phenylpyruvate, 0.8 ml of 2.5 N NaOH was added. The absorbance of the phenylpyruvate chromophore was read at 320 nm. We set up a blank with no enzyme for every reaction to account for the nonenzymatic conversion of chorismate to prephenate and added the enzyme after NaOH addition. The A 320 for the blank varied from 0.1 to 0.3, depending on the concentration of chorismate and duration of the reaction. The wild-type and the Glu 109 Gln mutant enzymes were assayed over a broad pH range using a universal buffer (33) .
Molecular mass determination of *MtCM. We determined the molecular mass of *MtCM by liquid chromatography-mass spectrometry and of the mutant forms via matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Mass spectra were collected and analyzed using an Applied Biosystems Voyager-DE STR Biospectrometry Workstation (Foster City, CA).
Crystallization. Crystallization conditions were surveyed by the hanging drop vapor diffusion method using a Hampton Research Crystal Screen Kit I. *MtCM was purified from the pRE1/Rv1885c recombinant and adjusted to a concentration of 8.3 mg/ml in 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM DTT, and 100 mM sodium chloride. The refined conditions used a well solution of 0.1 M morpholineethanesulfonic acid, pH 6.5, and 30% polyethylene glycol 8000. The crystals grew as thin plates and grew best between 25°C and 30°C. Seeding was used to reduce the number of crystals in each drop, and the polyethylene glycol 8000 was lowered to 14% to 18%.
Data collection. Diffraction data were collected at Industrial Macromolecular Crystallography Association Collaborative Access Team beamline 17ID-B at the Advanced Photon Source of Argonne National Laboratory (Argonne, IL) using a Mar Research charge-coupled-device detector. The wavelength for the data collection was 1 Å. For data collection at 100 K, the crystals were dipped in a solution made by mixing the well solution and 50% polyethylene glycol in a 1:1 ratio. The data were processed using X-GEN (19) , and the statistics are shown in Table 1 .
Structure determination. The structure of *MtCM was solved by molecular replacement using PHASER (35) with the partially refined structure of CM from Yersinia pestis (unpublished data). The asymmetric unit includes a dimer of *MtCM. REFMAC5 (37) was used to refine the model, and RESOLVE (54) was used to iteratively rebuild the model to remove bias. The refining and rebuilding were repeated. The final refinement statistics are shown in Table 1 . XtalView (36) was used to view the model graphically and to build portions not built by RESOLVE. The stereochemistry was checked with PROCHECK (28) and with MolProbity (31) . The Ramachandran plot in PROCHECK has 96.0% in the most favored region and 4% in the additional allowed region. The clash score from MolProbity for all atoms is 4.3, and for atoms with B values less than 40, the clash score is 2.56. Eleven residues in chain A and 11 residues in chain B of the dimeric *MtCM were modeled with two alternative conformations. No interpretable density was found for the first two residues, 34 and 35, of chain B, and the corresponding residues in chain A are not well ordered either (the numbering of the residues includes the 33-amino-acid signal sequence which is cleaved off in the mature protein).
Other methods. Protein concentration was determined according to the method of Lowry et al. using bovine serum albumin as the calibration standard (32) with the appropriate buffer in which the protein was purified as the blank. DNA sequence was determined by the dideoxy sequencing method (47) as adapted for the Applied Biosystems model 3100 Genetic Analyzer.
RESULTS AND DISCUSSION
*MtCM is secreted in M. tuberculosis H 37 R v . It is established that the Rv1885c gene product is synthesized with a signal peptide, which is cleaved off upon heterologous expression in E. coli, and transported into the periplasmic space (42, 48; Patterson et al., Am. Soc. Microbiol. Biodefense Res. Meet., abstr. 173, 2004) (Fig. 1, lane 4) . One difference in the cellular architecture of the gram-negative E. coli and the gram-positive M. tuberculosis is that there is no discrete periplasmic space in M. tuberculosis, although a pseudoperiplasmic space might exist (39) . Therefore, we asked the question, where is the mature *MtCM destined in its native environment? In order to probe for the cellular location of *MtCM, we tested the M. tuberculosis culture filtrate for CM activity. As shown in Fig. 2A , a reliable volume-dependent linear activity for CM was observed in the culture filtrate of a laboratory strain of M. tuberculosis (a superimposable result was observed for the culture filtrate from a clinical isolate). The CM activity in the culture filtrate from the cells in the late exponential phase of growth (3-weekold culture) was approximately twofold higher than that observed with the culture filtrate from the cells in the early exponential phase of growth (1-week-old culture). We wondered if the detection of CM in the culture filtrate was due to lysis of mycobacterial cells. If cell lysis were to occur, then the activity for CM in the culture filtrate cannot be attributed solely to *MtCM because a second gene (Rv0948c) for a cytoplasmic CM exists in M. tuberculosis (5, 7, 42, 48) . We therefore performed two control experiments using the diluted cell extract prepared as described in Materials and Methods. First, we assayed the diluted cell extract for CM. The results in Fig.  2A clearly show that CM activity in the cell extract from late exponential phase cells is Ϸ10-fold lower than that observed in the culture filtrate from the same batch of cells. Since CM activity in the cell extract is substantially lower than that present in the culture filtrate, we can attribute the CM activity in the culture filtrate as arising due to *MtCM but not due to the cytoplasmic Rv0948c CM. It has been reported (42) and we also observed (unpublished results) that the catalytic rate constant of Rv0948c CM is Ϸ1/50 that of *MtCM. Admittedly, the interpretation of the results would have been difficult if we had found equal or higher activity for CM in the cell extract than in the culture filtrate. Further, as a second control for cell lysis, a cytoplasmic Krebs cycle enzyme (44) , MDH, was assayed in the culture filtrate as well as in the diluted cell extract by following the reduction of NAD ϩ to NADH by a sensitive spectrophotometric assay. MDH was detected only in the cell extract but not in the culture filtrate (Fig. 2B) . This control experiment clearly shows that M. tuberculosis cells are not lysed under the growth conditions described. The results presented in this section demonstrate for the first time that *MtCM is secreted out of the cytoplasm and through the unusual architecture of the mycobacterial cell wall (3) into the culture medium. Secreted CMs have been shown to occur in the periplasm of Salmonella enterica serovar Typhimurium (4), Pseudomonas aeruginosa (4), and E. herbicola (56) . Indeed, a periplasmic biosynthetic pathway for phenylalanine was demonstrated in P. aeruginosa (4) . While it is intriguing to speculate about such a periplasmic pathway in M. tuberculosis, the lack of a discrete periplasmic compartment in this organism and the secretion of *MtCM from the cells into the culture medium preclude such a pathway. The biological significance of this highly active and secreted CM is discussed later.
Determination of the quaternary structure of *MtCM. *MtCM protein was purified to near homogeneity as described in Materials and Methods (Fig. 3, lane 4) . Purification of the 
Refinement
Resolution limits (Å investigated the quaternary structure of *MtCM by gel filtration chromatography at various protein concentrations ranging from 61 M down to 1 M and reported a dimeric nature of the protein in this concentration range. We performed size exclusion chromatography on a 480-ml Sephadex G-75 superfine column using 18.5 g of protein in 1 ml (500 nM concentration based on the molecular mass of 36,948 Da) and 2.5 g of protein in 1 ml (67.6 nM). Based on the activity analysis for CM, the protein was eluted with a peak activity at an identical elution volume corresponding to its dimeric molecular mass. Further, as the protein was eluted with a dilution factor of about 15-fold from the column, *MtCM exists in the dimeric form at a concentration as low as Ϸ5 nM. This observation suggests a tight association of the monomers despite a small interface between the monomers in the crystal structure of the dimer. Kinetic properties of *MtCM. Enzymatic assays were performed with the protein purified from the periplasm to see how efficiently *MtCM catalyzes the conversion of chorismate to prephenate. We determined the K m for chorismate at a protein concentration of 27.5 nM as well as at 8 nM (data not shown). *MtCM is active as chorismate mutase with a k cat of 60 Ϯ 4 s Ϫ1 per active site at 37°C and pH 7.5. *MtCM exhibited a simple hyperbolic response to chorismate at concentrations in the range of 0.1 mM to 5 mM, characteristic of Michaelis-Menten kinetics. The K m for chorismate was calculated from Lineweaver-Burk plots (data not shown). We observed a small but reproducible variation in the K m depending on the protein concentration used. A lower K m of 0.50 Ϯ 0.05 mM was obtained with a 27.5 nM protein concentration (11 pmol) whereas a K m of 0.67 Ϯ 0.05 mM was obtained with an 8 nM protein concentration (3.2 pmol). 
ml. The
A 320 value, after subtraction of the absorbance observed with the control, is recoded on the y axis. The effect of growth medium on purified *MtCM activity was tested and found to have no effect on either the nonenzymatic or enzymatic conversion of chorismate to prephenate. Early exponential phase cells are 1-week-old cells; late exponential phase cells are 3-week-old cells. ■, culture filtrate from early exponential phase cells; OE, culture filtrate from late exponential phase cells; F, cell extract from late exponential phase cells. CM activity levels in the culture filtrate from late exponential phase cells of a clinical isolate and a laboratory strain of M. tuberculosis were identical. (B) Assay for MDH in the culture filtrate and cell extract of M. tuberculosis H 37 R v . MDH was assayed as described in Materials and Methods. ■, culture filtrate from late exponential phase cells; OE, cell extract from late exponential phase cells. (42) reported a K m of 0.18 mM and 1.2 mM, respectively, with a sixfold difference. These differences in the K m among the three reports may be reconciled by the manner in which the enzyme was purified, the temperature of the reaction assay, and whether the assay was performed as a "stop assay" by measuring phenylpyruvate (converted from prephenate) at 320 nm (42) or as an "online assay" by following the disappearance of chorismate at 274 nm (48) , and, to an extent, how much protein was used in the assay as we point out here. We purified *MtCM as an untagged native protein and determined the K m by the stop assay at 37°C. Sasso et al. (48) used a heat denaturation step to remove most of the E. coli proteins, followed by ion exchange chromatography, and the assay was performed online at 30°C. Prakash et al. (42) purified the protein with a carboxyl terminal His 6 tag and performed the stop assay at 30°C. These differences among the three protocols for purification of the protein, the enzyme concentration used in the assay, and the type and conditions of the assay may explain the observed variations for the K m . While the pH 7.5 of the assay appears to be constant among the three protocols, a slight variation in the pH might have also contributed to the differences in the K m in view of a detailed study by Sasso et al. (48) , who have shown a 20-fold variation in the K m values as a function of pH values between 5 and 8. This can be rationalized by the existence of a glutamate residue (Glu 109 ) that needs to be protonated for optimum activity, as we have studied in detail and described later. In order to resolve this issue and classify *MtCM with regard to its allosteric regulation, we tested the effect of phenylalanine, tyrosine, and tryptophan on *MtCM activity under various conditions. We performed a number of experiments using 3.2 pmol of the protein with 2 mM chorismate as well as using 5 pmol and 11 pmol of the protein with 1 mM chorismate. We observed no effect on the activity by these aromatic amino acids other than an experimental variation of Ϯ5% (a representative set of data is shown in Fig. 4 ). Our detailed investigation on the effect of the aromatic amino acids on *MtCM clearly shows no feedback regulation of the enzyme, consistent with the results of Sasso et al. (48) and in disagreement with the results of Prakash et al. (42) . Our data generated from the stop assay is in agreement with the results of Sasso et al. (48) , who performed the online assay. Prakash et al. (42) performed the stop assay, and so did we. Therefore, the type of the assay, the amount of protein used in the assay, and the temperature of the reaction for determining the effect of aromatic amino acids on *MtCM activity are not the obvious reasons for this discrepancy. However, we found a couple of differences in the composition of the reaction medium described by Prakash et al. (42) . The investigators used 10 mM Tris-HCl, pH 7.5, in their assay, whereas we used 50 mM Tris-HCl, pH 7.5, in our assay, as recommended by the procedure described by Davidson and Hudson (9) . The low 10 mM concentration of the buffer may not be sufficient to keep the pH constant upon the addition of chorismic acid and the aromatic amino acids. We carried out extensive measurements on the activity of the wild type and the Glu 109 Gln mutant *MtCM as a function of pH as shown later (see Fig. 8 ). Our results show how strongly the activity of the wild-type enzyme can be inhibited at alkaline pH. Sasso et al. (48) have also documented how dramatically the K m changes with pH, with a consequential effect on the catalytic efficiency, k cat /K m . We believe that experimental artifacts with the rather sensitive chorismate mutase assay are the reasons for the observed complex regulation of *MtCM by the aromatic amino acids as reported by Prakash et al. (42) . Consistent with our observation that *MtCM is not regulated by the aromatic amino acids, the X-ray structure of *MtCM does not have an allosteric regulatory site in the protein (see below). Lambert et al. (27) , while working with the *AroQ homolog from the phytoparasitic nematode Meloidogyne javanica, also did not find any regulation by the aromatic amino acids. It Phenylalanine, tyrosine, and tryptophan were preincubated at the indicated concentrations with 3.2 pmol of *MtCM at 37°C for 5 min in 0.21 ml. The reaction was started with 0.2 ml of 4 mM chorismate, which was preincubated at 37°C for 5 min, to a final concentration of 2 mM. The reaction was allowed to proceed for 5 min. The final concentration of the Tris-HCl buffer was 50 mM, pH 7.5. An appropriate blank without the enzyme was included for every reaction, and the A 320 value was subtracted from the A 320 value with the enzyme. Tyrosine was used only up to a 1 mM final concentration since the solubility of this amino acid is poor at neutral pH. The catalytic rate constant, k cat , of *MtCM without any aromatic amino acid present in the assay is 62 s Ϫ1 .
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CHORISMATE MUTASE OF M. TUBERCULOSIS 8643 on November 16, 2019 by guest http://jb.asm.org/ therefore appears that *AroQ CM regulated by the aromatic amino acids is yet to be discovered. Overall structure of *MtCM and comparison with other CM structures. CMs have evolved with different structural folds for catalyzing the pericyclic rearrangement of chorismate to prephenate. The genetically engineered 109-amino-acid EcCM (29) (AroQ ␣ subclass) and the 256-amino-acid ScCM (58) (AroQ ␤ subclass) function as dimers and are ␣-helical bundles. *MtCM belongs to the secreted subclass of CMs (*AroQ [4] ), which was very recently renamed as the ␥ subclass of AroQ (AroQ ␥ ) CMs (40) . The 127-residue B. subtilis CM (BsCM) (6, 26) (AroH class) and the 122-residue T. thermophilus CM (TtCM) (17) (AroH class) function as trimers with ␣-helices and ␤-sheets. Despite the differences in the structural folds among the CMs, these enzymes display remarkable similarity in their active sites. The ScCM (49) and A. nidulans CM (AnCM) (25) are a step further apart in that these enzymes display allosteric regulation by tryptophan and tyrosine whereas EcCM and BsCM are not regulated by the aromatic amino acids. However, the AroH class TtCM was shown to be inhibited by tyrosine (17) . Due to the structural and functional diversity that exists among the CMs, we determined the threedimensional crystal structure of *MtCM. As shown in Fig. 5 , the 166-residue mature *MtCM protein forms an ␣-helical bundle with 10 helices, as defined by PROMOTIF (22) . Eightysix percent of the residues in *MtCM are included in helices, and one disulfide bond between Cys 160 and Cys 193 was observed. Sasso et al. (48) suggested an intramolecular disulfide bond between these two cysteine residues based on studies with reductants. *MtCM forms a dimer by the interactions defined in Table 2 which involve mainly residues in helix 4. The dimer is the same as that observed in the secreted CM from Y. pestis (unpublished data). We used the web service DALI (18) for automated superimposition of the refined structure on pro-teins included in the PDB (2) to look for structural neighbors. The two top hits were PDB 1ECM (EcCM) and PDB 5CSM (ScCM).
Crystal structure analysis of *MtCM reveals the catalytic site. In the known structures of CMs such as EcCM (29) and BsCM (6, 26) and the modeled structure of TtCM (17) , the active sites are formed from the contribution of residues from two chains whether these proteins function as dimers or trimers. The active site of *MtCM is made up of residues from a single chain ( Fig. 6A ) whereas in EcCM one critical residue, Arg 11 , from the second chain of the dimer contributes to the active site ( Fig. 6B ). While this article was in preparation, we found a similar structural analysis of *MtCM by Ö kvist et al. (40) . Ö kvist et al. also determined the structure with an endooxabicyclic transition state analog inhibitor, thus revealing the active-site residues in *MtCM. The analysis of our structure without the transition state analog but using the very close similarity to the EcCM structure with the transition state analog revealed the active-site residues identical to those identified by Ö kvist et al. (40) . In the next diagram, the EcCM dimer is shown with one monomer blue and the other monomer salmon. In the third diagram (from left), the monomer of ScCM is shown with the N-terminal part of the chain in blue and the C-terminal part of the same chain in salmon. Tryptophan (green) is shown in the regulatory site of ScCM; this is also the region of dimer contact in ScCM. In the far right diagram, the dimer of *MtCM is shown with one monomer colored according to the scheme used for the first diagram; the second monomer is shown in a lighter blue and pink. The main residues of the active site are shown as stick atomic models in green. The residues involved in the dimer interface are listed in Table 2 ; they are shown here as stick models in yellow. The structure analysis of *MtCM presented here and by Ö kvist et al. (40) and Qamra et al. (43) show an interesting feature of its active site and a novel fold topology for the protein. The active site is formed from a single chain in the dimer similar to that observed for ScCM (57) . The catalytic site of EcCM is formed from the residues Arg 28 , Lys 39 , Arg 51 , Ser 84 , and Gln 88 from one chain and Arg 11 from the second chain ( Fig. 6B) (29) . The residues that contribute to the active site in *MtCM are Arg 49 , Lys 60 , Arg 72 , Thr 105 , Glu 109 , and Arg 134 (Fig. 6A) ; the numbering of the amino acids includes the signal sequence. MacBeath et al. (33) and Sasso et al. (48) already predicted all the active-site residues of *MtCM based on sequence alignments. Superimposition of the active site of one monomer of *MtCM onto one of the active sites of EcCM shows that a single chain of *MtCM covers most of the dimer of EcCM (Fig. 6C ). This observation raises the question as to why *MtCM functions as a dimer. We have begun experiments to investigate this point. In this context it is pertinent to mention that MacBeath et al. (34) generated a monomeric form of Methanococcus jannaschii CM which is catalytically as efficient as the naturally occurring dimer.
Qamra et al. (43) , in their structure analysis of *MtCM, showed a binding site for tryptophan at the small dimer interface despite overwhelming evidence that *MtCM is not regulated by any of the aromatic amino acids ( Fig. 4) (48) . Further, we clearly demonstrated that *MtCM is secreted out of M. tuberculosis cells. Since the shikimate pathway is absent in mammals, the M. tuberculosis host, *MtCM must not have any function in the nonexistent aromatic amino acid biosynthetic pathway. Hence, it is not scientifically tangible to have such an enzyme allosterically regulated by the aromatic amino acids as previously published (42, 43) .
Mutagenesis of the conserved amino acid residues in *MtCM reinforces the catalytic site. We performed site-directed mutagenesis of the putative active-site residues based on the structure analysis presented here as well as based on the sequence alignment (48) . We selected Arg 49 , Lys 60 , Asp 69 , Arg 72 , Thr 105 , Glu 109 , and Arg 134 for mutagenesis. All the residues were mutated to alanine. Additionally, Glu 109 was mutated to Gln for two reasons: (i) the CM Ec counterpart of this residue, Gln 88 , is an active-site residue (30) , and (ii) we wanted to explore the role of this residue in catalysis as a function of pH since the ScCM counterpart of this residue is Glu 246 which has been shown to be protonated for optimal activity (49) .
Translocation of *MtCM into the periplasmic compartment of E. coli is shown in Fig. 1 (lane 4) . The wild-type and the mutant proteins were purified under identical conditions from the periplasmic fluid of the respective clones [pET15b recombinant/BL21(DE3)] to homogeneity in a single chromatographic step as described in Materials and Methods (SDS-PAGE results not shown). We observed an identical elution behavior for all the mutant proteins as the wild-type enzyme on the molecular sieve Biosep SEC-3000 HPLC column. The mutant proteins were assayed for CM activity at a 12.5 nM concentration (5 pmol). The results of the mutagenesis and the activity analysis show that Arg 49 , Lys 60 , Arg 72 , and Arg 134 are essential for catalysis, having only Յ1% of the wild-type enzyme activity (Table 3 ). Thr 105 Ala and Glu 109 Ala mutations resulted in having 20% and 10% activity, respectively, and therefore are also catalytic site residues. Based on the mutagenesis data presented here and the complementary data from the crystal structure of *MtCM with the transition state analogue (TSA) determined by Okvist et al. (40) , we propose that the active-site residues in *MtCM correspond to the active-site residues in EcCM as follows: *MtCM Arg 49 is EcCM Arg 28 ; *MtCM Lys 60 is EcCM Lys 39 ; *MtCM Arg 72 is EcCM Arg 51 ; *MtCM Thr 105 is EcCM Ser 84 ; *MtCM Glu 109 is EcCM Gln 88 , and *MtCM Arg 134 is EcCM Arg 11 . An interaction between the main chain nitrogen of Asp 69 and the C 4 hydroxyl group of chorismate is proposed to be analogous to the interactions in the catalytic site of EcCM (Fig. 7) . Mutation of Asp 69 to alanine has no effect on the enzyme activity (Table   FIG. It is notable that in *MtCM all the active-site residues are from the same chain, whereas in EcCM residues from both chains contribute to the active site (29) . In panel C, the dimer of EcCM is superimposed onto one monomer of the *MtCM dimer. 3), as would be expected unless the specific side chain had an influence on the backbone conformation. We focus our discussion on the variant glutamate/glutamine at the corresponding positions in various CMs. The activity of the wild-type *MtCM with Glu 109 was optimal under broad acidic conditions with only a slight increase in the activity from pH 4.0 (k cat ϭ 55 Ϯ 3 s Ϫ1 ) to pH 6.5 (k cat ϭ 69.5 Ϯ 4.5 s Ϫ1 ) ( Fig. 8 ). While the activity of the wild-type enzyme was stable up to pH 7.5 (k cat ϭ 66.5 Ϯ 4.5 s Ϫ1 ), the activity was dramatically affected under alkaline conditions (k cat ϭ 10.8 Ϯ 3 s Ϫ1 at pH 9.5). A broad pH tolerance from pH 4.0 to 7.5 for optimal activity of *MtCM is in sharp contrast to the pH optimum observed for ScCM with Glu 246 (49) and AnCM (25) with Glu 253 in the corresponding positions. ScCM (49) and AnCM (25) exhibit a bell-shaped curve at pH 5.5 and pH 5.9, respectively, having only 5% to 10% of the activity at pH 4.0 and 25% to 35% of the activity at pH 7.5. Consistent with the fact that EcCM with a naturally occurring Gln 88 is an active enzyme (30) , we observed that the Glu 109 Gln mutation in *MtCM results in ca. 40% net activity at pH 7.5 ( Fig. 8 and Table 3 ). The Glu 109 Gln mutant of *MtCM exhibited ca. 27% of the wild-type activity at pH 4.0 (k cat ϭ 15 Ϯ 0.8 s Ϫ1 ). The activity of this mutant gradually increased to ca. 40% of the wild-type activity with an increase in pH to 7.5 (k cat ϭ 26.6 Ϯ 2 s Ϫ1 ) and remained constant up to pH 11.0, unlike the activity of the wild-type enzyme. While these results show that *MtCM is active at pH 4.0 and suggest a requirement for protonation of Glu 109 in *MtCM from the observed optimal activity in the acidic pH range, it is more difficult to explain why the enzyme is as active at pH 7.5 where protonation does not efficiently occur. It is conceivable that Glu 109 could have a perturbed elevated pK a as was demonstrated for a helicase catalyzing ATP hydrolysis (11) . Based on the structure of the wild-type protein and activity analysis of the mutant proteins, we propose that Arg 49 , Lys 60 , Arg 72 , Thr 105 , Glu 109 , and Arg 134 constitute the active site of *MtCM through hydrogen bonds and electrostatic interactions with chorismate ( Fig. 7) . In addition to these residues, Ö kvist et al. (40) proposed Gln 76 and Glu 106 as part of the catalytic site based on the structure with the TSA.
What , have experimentally demonstrated in a heterologous E. coli expression system that *MtCM is secreted into the periplasmic compartment. First of all, there is no discrete periplasmic compartment in the gram-positive M. tuberculosis although there is a report of possible existence of a pseudoperiplasmic compartment in this organism (39) . Hence, the cellular location/dislocation of the *AroQ is another emerging attribute of CMs. So, where is *MtCM expected to be localized in its native environment? To answer this question, we tested the M. tuberculosis culture filtrate for CM activity. We found CM activity in the culture filtrate of early exponential phase and late exponential phase cells ( Fig. 2A) The diagram depicts the hydrogen bonds and electrostatic contacts between the amino acid residues and chorismate in the center. Although we did not determine the structure of *MtCM with a TSA, we predict that the contacts will be identical to those of the EcCM structure with the TSA except that Arg 134 from the same chain contributes to the active site.
FIG. 8. pH dependence of the wild-type (WT) *MtCM and the mutant Glu 109 Gln. The wild-type and the mutant proteins were assayed using 11 pmol of *MtCM over a broad pH range in a universal buffer (33) . The reaction was carried out at 37°C and terminated after 1 min when the wild-type enzyme was used or after 3 min when the mutant enzyme was used. Chorismate was used at a 1 mM concentration. a Each protein was assayed for CM activity at 37°C using 5 pmol of the protein (purified from the periplasmic components of E. coli) and 1 mM chorismate. The pH of the reaction was 7.5. The reaction was allowed to proceed for 1 to 5 min, depending on the activity, and was terminated with HCl. The results are the average of two experiments. The 100% wild-type CM activity has a k cat of 60 s Ϫ1 per active site (at 37°C and pH 7.5). existent shikimate pathway in the macrophages of mammals, the target of M. tuberculosis infection. If *MtCM were to function in pathogenesis or virulence of M. tuberculosis, why has it evolved to be chorismate mutase? This needs further investigation.
The success of M. tuberculosis as a persistent pathogen lies in its interaction with the host macrophages and inhibition of the maturation of phagosomes to phagolysosomes (41) . While there may be a number of mechanisms responsible for the arrest of phagosome maturation by M. tuberculosis, we would like to propose a possible role in this process for *MtCM. As we demonstrated here, *MtCM is active at pH 4.5 (Fig. 8 ) and therefore should maintain its structural integrity in the acidic pH range. A probable reason for *MtCM to have a broad acidic pH range may have to do with its destination in the M. tuberculosis-infected macrophage environment, which is acidic (53) . *MtCM may have some unappreciated role in the hostpathogen interaction. Finally, as the shikimate pathway enzymes are not present in humans, these enzymes are often considered as therapeutic targets. Although the secreted CM is not as attractive as a drug target as an intracellular CM, knockout for the Rv1885c-encoded secreted CM might prove to be useful as a vaccine candidate. What can be better to combat a debilitating disease caused by the pathogen M. tuberculosis, which claims about 8 million humans per year (50), than to use basic science to interrupt the shikimate pathway?
